Introduction {#tca13229-sec-0008}
============

Small cell lung cancer (SCLC) is a highly aggressive malignancy characterized by rapid tumor growth, early locoregional and distant metastases, and frequent presentation of paraneoplastic syndromes.[1](#tca13229-bib-0001){ref-type="ref"} Despite a high response rate to chemotherapy, the one‐year survival percentage in patients with extensive‐stage disease (ED) SCLC is only 25%--41%.[2](#tca13229-bib-0002){ref-type="ref"}, [3](#tca13229-bib-0003){ref-type="ref"}, [4](#tca13229-bib-0004){ref-type="ref"} Old age, poor performance status (PS), serum creatinine levels above the upper normal limit, and elevated serum lactate dehydrogenase levels are known to be poor prognostic factors in patients with ED‐SCLC.[5](#tca13229-bib-0005){ref-type="ref"}, [6](#tca13229-bib-0006){ref-type="ref"}

Nutritional status is increasingly recognized as an important prognostic factor in cancer patients. Malnutrition and cachexia are associated with intolerance to anticancer therapy, reduced physical activity, and decreased survival.[7](#tca13229-bib-0007){ref-type="ref"}, [8](#tca13229-bib-0008){ref-type="ref"} Various markers for nutritional status and cachexia have previously been evaluated in SCLC. Sarcopenia and adipopenia measured by computed tomography have been reported to be related to early discontinuation of treatment and to reduced survival.[9](#tca13229-bib-0009){ref-type="ref"}, [10](#tca13229-bib-0010){ref-type="ref"} A low modified Glasgow prognostic score (GPS) consisting of serum albumin and C‐reactive protein levels was also reported to be associated with shorter overall survival (OS).[11](#tca13229-bib-0011){ref-type="ref"} The prognostic nutritional index (PNI) has been evaluated in several retrospective studies, which consistently reported an association between low PNI values and poor prognoses in patients with SCLC.[11](#tca13229-bib-0011){ref-type="ref"}, [12](#tca13229-bib-0012){ref-type="ref"}, [13](#tca13229-bib-0013){ref-type="ref"}, [14](#tca13229-bib-0014){ref-type="ref"} The Geriatric Nutritional Risk Index (GNRI) is another simplified parameter, which was developed to determine the risk of nutrition‐related morbidity and mortality in elderly noncancer patients.[15](#tca13229-bib-0015){ref-type="ref"} The low level of this index has been reported to be associated with frequent surgical complications[16](#tca13229-bib-0016){ref-type="ref"}, [17](#tca13229-bib-0017){ref-type="ref"}, [18](#tca13229-bib-0018){ref-type="ref"} and with reduced survival[19](#tca13229-bib-0019){ref-type="ref"}, [20](#tca13229-bib-0020){ref-type="ref"}, [21](#tca13229-bib-0021){ref-type="ref"} in various solid tumors. However, the clinical impact of the GNRI on SCLC have not previously been reported.

Etoposide plus platinum (EP) combination chemotherapy have been considered the standard first‐line treatment for ED‐SCLC.[2](#tca13229-bib-0002){ref-type="ref"}, [22](#tca13229-bib-0022){ref-type="ref"}, [23](#tca13229-bib-0023){ref-type="ref"} Additionally, the irinotecan plus platinum (IP) regimen has been suggested as a potent alternative therapy.[24](#tca13229-bib-0024){ref-type="ref"}, [25](#tca13229-bib-0025){ref-type="ref"}, [26](#tca13229-bib-0026){ref-type="ref"} A meta‐analysis showed a significant benefit of OS for IP over EP with a different toxicity profile.[27](#tca13229-bib-0027){ref-type="ref"} However, it is debatable whether irinotecan can substitute for etoposide because this meta‐analysis did not use individual patient data and showed only a relatively small absolute survival benefit without a benefit in terms of progression‐free survival (PFS). Furthermore, the results, which favored irinotecan in Asian patients, were not reproduced in non‐Asian patients.[4](#tca13229-bib-0004){ref-type="ref"}, [28](#tca13229-bib-0028){ref-type="ref"} Recently, our previous phase III study which was conducted in Korean patients reported that there was no significant difference in OS between IP and EP (median OS: 10.9 vs. 10.3 months, respectively, *P* = 0.120).[29](#tca13229-bib-0029){ref-type="ref"} Preplanned subgroup analysis showed that the IP regimen might be favorable in males and younger ages, with a good PS and a modest survival benefit of 5--6 weeks. This secondary analysis was conducted to evaluate the prognostic values of the GNRI and other nutritional markers in patients with ED‐SCLC, and to further select patients who would benefit from either the IP or EP regimens through stratification using the GNRI.

Methods {#tca13229-sec-0009}
=======

Patients and study design {#tca13229-sec-0010}
-------------------------

This analysis used data from our previous randomized, multi‐center, phase III trial, which compared the efficacy of the IP regimen with that of the EP regimen in ED‐SCLC patients. The study design, eligibility, and treatment schedule have been previously described.[29](#tca13229-bib-0029){ref-type="ref"} Briefly, the study involved 362 eligible patients ≥18 years of age having histologically or cytologically confirmed ED‐SCLC, no previous chemotherapy, Eastern Cooperative Oncology Group (ECOG) PS ≤ 2, and measurable lesions as defined by the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0.[30](#tca13229-bib-0030){ref-type="ref"} Patients also had adequate organ function. Enrolled patients were randomly (1:1) treated with either the IP or EP regimen. The patients assigned to the IP arm received 65 mg/m^2^ of irinotecan on days 1 and 8 and 70 mg/m^2^ of cisplatin on day 1 every three weeks. Those assigned to the EP arm received 100 mg/m^2^ of etoposide on days 1--3 and 70 mg/m^2^ of cisplatin on day 1 every three weeks. Up to six cycles of chemotherapy were allowed in each arm. In the present study, 10 of 362 patients in whom the GNRI could not be calculated were excluded. The study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki, and approved by the Institutional Review Board of each participating institution. All patients provided written informed consent.

Evaluation and definition {#tca13229-sec-0011}
-------------------------

Before treatment, all patients were evaluated using demographic information, physical measurements, ECOG PS, radiological studies, and laboratory tests, including a complete blood cell count and serum chemistry. Tumor response to treatment was assessed according to the RECIST version 1.0 every 2--3 cycles of treatment.[30](#tca13229-bib-0030){ref-type="ref"} Treatment‐related toxicity was evaluated using National Cancer Institute Common Toxicity Criteria, version 3.0, every treatment cycle. Body mass index (BMI) was calculated as bodyweight (kg) divided by the square of the height (m^2^). Underweight was defined as a BMI \< 18.5 kg/m^2^ according to Asian criteria.[31](#tca13229-bib-0031){ref-type="ref"} PNI was calculated as 10 × serum albumin level (g/dL) + 0.005 × absolute lymphocyte count (/mm^3^). PNI values \>45, 40--45, and \<40 were categorized as low, intermediate, and high risk.[32](#tca13229-bib-0032){ref-type="ref"} GNRI values were calculated as 1.489 × serum albumin level (g/L) + 41.7 × (actual bodyweight \[ABW\]/ideal bodyweight \[IBW\] \[kg\]). The ABW/IBW ratio was set to one if the ABW exceeded the IBW. GNRI values \>98, 92--98, and \<92 were categorized as no, low, and moderate/major risk as described previously.[15](#tca13229-bib-0015){ref-type="ref"}

Statistical analysis {#tca13229-sec-0012}
--------------------

All analyses were performed on an intention‐to‐treat population. The correlations between ordinal and continuous variables and those between ordinal and dichotomous variables were tested using Spearman\'s rank correlation and the chi‐square for trend tests, respectively. OS was calculated as the time from the date of beginning treatment to the date of death or the last follow‐up. PFS was calculated as the time from the date of beginning treatment to the date of progression, death, or last follow‐up. Survival was analyzed using the Kaplan‐Meier method and compared by the log‐rank test for trend. Cox regression analysis was performed to determine the influence of different variables on survival. All variables with a *P*‐value \<0.05 on univariate analyses and treatment regimen were included in the multivariate Cox regression model. A two‐sided *P*‐value \<0.05 was considered statistically significant. All analyses were performed with STATA software, version 14.2 (College Station, TX, USA).

Results {#tca13229-sec-0013}
=======

Baseline characteristics {#tca13229-sec-0014}
------------------------

The mean (± standard deviation) GNRI value was 94.7 (± 8.8) with a range of 68.5--113.2. Of 352 patients, 133 were assigned to the no risk group, 95 to the low risk group, and 124 to the moderate/major risk group. Their baseline characteristics according to GNRI are presented in Table [1](#tca13229-tbl-0001){ref-type="table"}. In total, the median age was 65 years (range: 36--81 years) and most patients were male (90.3%). A poor ECOG PS of two was observed in 51 patients (14.5%). Brain metastasis was detected at diagnosis in 94 patients (26.7%). In a comparison of the three GNRI groups, there was no statistically significant difference in age, sex, brain metastasis, chemotherapy regimen, or thrombocytopenia incidence. However, poor PS (*P* \< 0.001), anemia (*P* \< 0.001), and hyponatremia (*P* = 0.013) were more common in the moderate/major risk group. The values of other nutritional markers such as BMI (*P* \< 0.001) and PNI (*P* \< 0.001) were higher as the GNRI value increased.

###### 

Baseline characteristics

  Characteristics                GNRI \> 98 (*n* = 133)   GNRI 92--98 (*n* = 95)   GNRI \< 92 (*n* = 124)   *P*‐value
  ----------------------------- ------------------------ ------------------------ ------------------------ -----------
  Age                                                                                                      
  \<65 years                           65 (48.9)                46 (48.4)                49 (39.5)            0.136
  ≥65 years                            68 (51.1)                49 (51.6)                75 (60.5)         
  Median, years (range)               65 (36--80)              65 (47--81)              66 (48--81)           0.066
  Sex                                                                                                      
  Male                                 123 (92.5)               84 (88.4)                111 (89.5)           0.414
  Female                                10 (7.5)                11 (11.6)                13 (10.5)         
  ECOG PS                                                                                                  
  0--1                                 122 (91.7)               86 (90.5)                93 (75.0)          \< 0.001
  2                                     11 (8.3)                 9 (9.5)                 31 (25.0)         
  Brain metastasis                                                                                         
  Absent                               58 (43.6)                39 (41.1)                46 (37.1)            0.143
  Present                              34 (25.6)                32 (33.7)                28 (22.6)         
  Not evaluated                        41 (30.8)                24 (25.3)                50 (40.3)         
  Regimen                                                                                                  
  IP                                   63 (47.4)                47 (49.5)                60 (48.4)            0.867
  EP                                   70 (52.6)                48 (50.5)                64 (51.6)         
  Anemia                                                                                                   
  Absent                               93 (69.9)                54 (56.8)                35 (28.2)          \< 0.001
  Present                              40 (30.1)                41 (43.2)                89 (71.8)         
  Thrombocytopenia                                                                                         
  Absent                               128 (96.2)               87 (91.6)                118 (95.2)           0.682
  Present                               5 (3.8)                  8 (8.4)                  6 (4.8)          
  Hyponatremia                                                                                             
  Absent                               105 (79.0)               77 (81.1)                81 (65.3)            0.013
  Present                              28 (21.1)                18 (19.0)                43 (34.7)         
  Median BMI (range), kg/m^2^      23.9 (17.9--34.8)        22.8 (15.0--28.3)        20.9 (14.8--27.8)      \< 0.001
  Median PNI (range)               54.7 (41.8--71.3)         47.9 (37.7--60)         41.4 (26.8--56.5)      \< 0.001

BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status; EP, etoposide/cisplatin; GNRI, Geriatric Nutritional Risk Index; IP, irinotecan/cisplatin; PNI, Prognostic Nutritional Index.

Treatment response {#tca13229-sec-0015}
------------------

Treatment response assessments were available for 287/352 patients (Table [2](#tca13229-tbl-0002){ref-type="table"}). There were three complete responses (CRs) in the no risk group, compared with only one CR in the other two groups. The objective response rates (ORRs) were 63.2%, 52.6%, and 49.2% in the no, low, and moderate/major risk groups, respectively (*P* = 0.024). Similar to our previous study,[29](#tca13229-bib-0029){ref-type="ref"} the ORR was significantly higher in the IP arm compared with the EP arm (62.4% vs. 48.9%, respectively; *P* = 0.011). Regardless of the chemotherapy regimen, the ORR tended to be lower in the moderate/major risk group, although there was no statistical significance (no vs. low vs. moderate/major risk group, 71.4% vs. 57.5% vs. 56.7% in the IP arm \[*P* = 0.090\]; 55.7% vs. 47.9% vs. 42.2% in the EP arm \[*P* = 0.118\], respectively).

###### 

Best overall response

  Confirmed best response              GNRI \> 98 (*n* = 133)   GNRI 92--98 (*n* = 95)   GNRI \< 92 (*n* = 124)
  ----------------------------------- ------------------------ ------------------------ ------------------------
  Complete response                           4 (3.0)                  0 (0.0)                  1 (0.8)
  Partial response                           80 (60.2)                50 (52.6)                60 (48.4)
  Stable disease                             25 (18.8)                24 (25.3)                23 (18.6)
  Progressive disease                         6 (4.5)                  4 (4.2)                  10 (8.1)
  Not evaluable                              18 (13.5)                17 (17.9)                30 (24.2)
  Objective response rate (CR + PR)          84 (63.2)                50 (52.6)                61 (49.2)

CR, complete response; GNRI, Geriatric Nutritional Risk Index; PR, partial response.

Toxicity {#tca13229-sec-0016}
--------

Grade 3 or more adverse events occurred in \>2% of patients were reviewed (Table [3](#tca13229-tbl-0003){ref-type="table"}). The mean (± standard deviation) treatment cycles were 4.7 (± 1.9), 4.4 (± 2.0), and 4.1 (± 2.2) in the no, low, and moderate/major risk groups (*P* = 0.014). The no risk group had significantly fewer incidences of anemia (14.3% vs. 25.3% vs. 26.6%; *P* = 0.016) and thrombocytopenia (4.5% vs. 17.9% vs. 17.7%; *P* = 0.001) compared with the low and moderate/major risk groups, respectively. Nausea was less common in the moderate/major risk group than the other two groups, but only small numbers of patients experienced this toxicity. Otherwise, there were no differences in neutropenia, neutropenic fever, infection, vomiting, diarrhea, and liver function test abnormalities among the three groups. Treatment‐related deaths and treatment discontinuations caused by toxicity occurred in three, six, and nine patients (2.3%, 6.3%, and 7.3%; *P* = 0.068) and in 13, 10, and 13 patients (9.8%, 10.5%, and 10.5%; *P* = 0.850) in the no, low, and moderate/major risk groups, respectively.

###### 

Grade ≥ 3 adverse events in more than 2% of subjects

  Adverse event        GNRI \> 98 (*n* = 133)   GNRI 92--98 (*n* = 95)   GNRI \< 92 (*n* = 124)   *P*‐value
  ------------------- ------------------------ ------------------------ ------------------------ -----------
  Anemia                     19 (14.3)                24 (25.3)                33 (26.6)            0.016
  Neutropenia                92 (69.2)                55 (57.9)                82 (66.1)            0.588
  Thrombocytopenia            6 (4.5)                 17 (17.9)                22 (17.7)            0.001
  Neutropenic fever          23 (17.3)                15 (15.8)                21 (16.9)            0.935
  Infection                  20 (15.0)                16 (16.8)                28 (22.6)            0.119
  Nausea                      5 (3.8)                  3 (3.2)                  0 (0.0)             0.045
  Vomiting                    4 (3.0)                  3 (3.2)                  1 (0.8)             0.242
  Diarrhea                    8 (6.0)                  8 (8.4)                  6 (4.8)             0.711
  AST elevation               3 (2.3)                  5 (5.3)                  2 (1.6)             0.780
  ALT elevation               3 (2.3)                  4 (4.2)                  1 (0.8)             0.453

AST, aspartate transaminase; ALT, alanine transaminase; GNRI, Geriatric Nutritional Risk Index.

Survival {#tca13229-sec-0017}
--------

The median follow‐up duration was 50.1 months (range: 17.6--83.2 months) in all patients. The median PFS was shorter in the moderate/major risk group than in the lower risk groups (no vs. low vs. moderate/major risk group, 6.5 \[95% CI: 6.0--7.2\] vs. 5.8 \[95% CI: 5.5--0.5\] vs. 5.9 \[95% CI: 4.8--6.4\] months; respectively; *P* = 0.028; Fig [1](#tca13229-fig-0001){ref-type="fig"}a). The difference was more apparent in the median OS among the three groups (no vs. low vs. moderate/major risk group, 13.2 \[95% CI: 11.7--4.7\] vs. 10.3 \[95% CI: 8.8--1.5\] vs. 8.4 \[95% CI: 7.4--10.0\] months, respectively; *P* \< 0.001; Fig [1](#tca13229-fig-0001){ref-type="fig"}b). In a comparison according to chemotherapy regimen, there was no significant difference in median PFS (6.5 vs. 5.9 months; *P* = 0.105) and OS (10.9 vs. 10.3 months; *P* = 0.241) between the IP and EP arms, respectively, as shown in our previous study.[29](#tca13229-bib-0029){ref-type="ref"} In the IP arm, there was no difference in median PFS among the three groups (no vs. low vs. moderate/major risk group, 6.9 \[95% CI: 6.3--7.4\] vs. 5.9 \[95% CI: 4.7--7.7\] vs. 6.2 \[95% CI: 5.3--7.2\] months, respectively; *P* = 0.307; Fig [2](#tca13229-fig-0002){ref-type="fig"}a), while the median OS was shorter in the moderate/major risk group compared with the lower risk groups (no vs. low vs. moderate/major risk group, 12.7 \[95% CI: 9.4--15.3\] vs. 10.3 \[95% CI: 7.3--15.6\] vs. 9.6 \[95% CI: 7.1--12.7\] months, respectively; *P* = 0.033; Fig [2](#tca13229-fig-0002){ref-type="fig"}b). In the EP arm, there were significant differences among the three groups both in median PFS (no vs. low vs. moderate/major risk group, 6.0 \[95% CI: 5.2--7.1\] vs. 5.7 \[95% CI: 4.5--6.7\] vs. 4.8 \[95% CI: 3.5--6.2\] months, respectively; *P* = 0.027; Fig [2](#tca13229-fig-0002){ref-type="fig"}c) and OS (no vs. low vs. moderate/major risk group, 13.3 \[95% CI: 11.8--16.0\] vs. 10.0 \[95% CI: 7.8--11.2\] vs. 7.7 \[95% CI: 6.7--9.1\] months, respectively; *P* \< 0.001; Fig [2](#tca13229-fig-0002){ref-type="fig"}d).

![Kaplan‐Meier curves for (**a**) progression‐free survival and (**b**) overall survival according to GNRI. GNRI, Geriatric Nutritional Risk Index. (![](TCA-11-62-g003.jpg "image")) GNRI \> 98 (*n* = 133), (![](TCA-11-62-g004.jpg "image")) GNRI 92--98 (*n* = 95) and (![](TCA-11-62-g005.jpg "image")) GNRI \< 92 (*n* = 124).](TCA-11-62-g001){#tca13229-fig-0001}

![Kaplan‐Meier curves for (**a**) progression‐free survival, (**b**) overall survival in the IP arm, and (**c**) progression‐free survival and (**d**) overall survival in the EP arm according to GNRI. EP, etoposide/cisplatin; GNRI, Geriatric Nutritional Risk Index; IP, irinotecan/cisplatin. (**a**, **b**) (![](TCA-11-62-g003.jpg "image")) GNRI \> 98 (*n* = 63), (![](TCA-11-62-g004.jpg "image")) GNRI 92--98 (*n* = 47) and (![](TCA-11-62-g005.jpg "image")) GNRI \< 92 (*n* = 60). (**c**, **d**) (![](TCA-11-62-g003.jpg "image")) GNRI \> 98 (*n* = 70), (![](TCA-11-62-g004.jpg "image")) GNRI 92--98 (*n* = 48) and (![](TCA-11-62-g005.jpg "image")) GNRI \< 92 (*n* = 64).](TCA-11-62-g002){#tca13229-fig-0002}

In a multivariate analysis of PFS (Table [4](#tca13229-tbl-0004){ref-type="table"}), being part of the moderate/major risk group was an independent poor prognostic factor (hazard ratio \[HR\]: 1.300; 95% CI: 1.012--1.670; *P* = 0.040). The low risk group did not show a statistically significant difference in PFS compared with the no risk group (*P* = 0.085). In a multivariate analysis of OS, being a member of either the low risk group (HR: 1.446; 95% CI: 1.086--1.925; *P* = 0.012) or the moderate/major risk group (HR: 1.539; 95% CI: 1.069--2.216; *P* = 0.020) was an independent poor prognostic factor, compared with the no risk group. In contrast, the PNI lost statistical significance after adjusting for potential prognostic factors, including the GNRI.

###### 

Cox regression for PFS and OS

  Factor                   PFS         OS                                                                                                      
  ---------------------- ------- -------------- ------- ------- -------------- ------- ------- -------------- --------- ------- -------------- -------
  Age                                                                                                                                          
  \<65 years              Ref.                                                          Ref.                             Ref.                  
  ≥65 years               1.065   0.861--1.318   0.563                                  1.328   1.067--1.652    0.011    1.305   1.045--1.629   0.019
  Sex                                                                                                                                          
  Male                    Ref.                                                          Ref.                                                   
  Female                  1.257   0.882--1.793   0.206                                  1.153   0.799--1.662    0.447                          
  ECOG PS                                                                                                                                      
  0--1                    Ref.                                                          Ref.                             Ref.                  
  2                       1.208   0.892--1.635   0.221                                  1.767   1.294--2.413   \<0.001   1.686   1.217--2.336   0.002
  Brain metastasis                                                                                                                             
  Absent/not evaluated    Ref.                                                          Ref.                                                   
  Present                 1.056   0.831--1.341   0.658                                  1.149   0.900--1.467    0.265                          
  Regimen                                                                                                                                      
  IP                      Ref.                           Ref.                           Ref.                             Ref.                  
  EP                      1.191   0.963--1.473   0.106   1.210   0.978--1.497   0.080   1.139   0.916--1.417    0.242    1.123   0.900--1.402   0.303
  Anemia                                                                                                                                       
  Absent                  Ref.                                                          Ref.                             Ref.                  
  Present                 1.157   0.937--1.430   0.176                                  1.288   1.037--1.602    0.022    1.106   0.863--1.418   0.426
  Thrombocytopenia                                                                                                                             
  Absent                  Ref.                                                          Ref.                                                   
  Present                 1.072   0.675--1.704   0.768                                  1.104   0.683--1.782    0.687                          
  Hyponatremia                                                                                                                                 
  Absent                  Ref.                           Ref.                           Ref.                             Ref.                  
  Present                 1.394   1.093--1.780   0.008   1.382   1.081--1.767   0.010   1.240   0.968--1.588    0.089    1.100   0.835--1.448   0.498
  BMI                                                                                                                                          
  Normal to obese         Ref.                                                          Ref.                                                   
  Underweight             1.175   0.798--1.731   0.414                                  1.370   0.908--2.067    0.134                          
  PNI                                                                                                                                          
  \>45                    Ref.                                                          Ref.                             Ref.                  
  40--45                  1.221   0.920--1.622   0.167                                  1.416   1.061--1.892    0.018    1.050   0.750--1.470   0.777
  \<40                    1.264   0.943--1.694   0.117                                  1.457   1.078--1.968    0.014    0.953   0.625--1.454   0.823
  GNRI                                                                                                                                         
  \>98                    Ref.                           Ref.                           Ref.                             Ref.                  
  92--98                  1.242   0.951--1.623   0.112   1.266   0.968--1.654   0.085   1.463   1.114--1.920    0.006    1.446   1.086--1.925   0.012
  \<92                    1.315   1.026--1.687   0.031   1.300   1.012--1.670   0.040   1.696   1.311--2.194   \<0.001   1.539   1.069--2.216   0.020

BMI, body mass index; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; EP, etoposide/cisplatin; GNRI, Geriatric Nutritional Risk Index; HR, hazard ratio; IP, irinotecan/cisplatin; OS, overall survival; PFS, progression‐free survival; PNI, Prognostic Nutritional Index.

Discussion {#tca13229-sec-0018}
==========

This report provides the first evidence of an association between the GNRI and the prognoses of patients with ED‐SCLC. The moderate/major risk group had a 14% reduction in the treatment response percentage and decreased survival by five months (median OS: 13.2 vs. 8.4 months) compared with the no risk group. Although poor PS, anemia, and hyponatremia in baseline characteristics were more commonly observed in the higher risk group, the GNRI remained an independent prognostic factor for survival after adjusting for these variables.

The underlying mechanism resulting in SCLC patients with a low GNRI having a poor prognosis is unclear. The GNRI consists of the serum albumin level and bodyweight (ABW/IBW). Because the ABW/IBW ratio is set to one if the ABW is greater than the IBW in the GNRI formula, the value of albumin outweighs that of bodyweight in the GNRI.[15](#tca13229-bib-0015){ref-type="ref"} Hypoalbuminemia is known to reflect a systemic inflammatory condition. Inflammatory cytokines such as interleukin‐1 and ‐6 reduce the hepatic synthesis of albumin and its mRNA content.[33](#tca13229-bib-0033){ref-type="ref"}, [34](#tca13229-bib-0034){ref-type="ref"} Tumor necrosis factor‐alpha increases the albumin permeability of glomeruli through the generation of superoxides.[35](#tca13229-bib-0035){ref-type="ref"} The transcapillary escape of albumin from the intravascular space to the tissue space is increased under inflammatory conditions, and is promoted by interleukin‐2.[36](#tca13229-bib-0036){ref-type="ref"}, [37](#tca13229-bib-0037){ref-type="ref"} Oxidative stress results in an increase in denatured albumin, which is likely to be degraded by endocytosis in hepatic endothelial cells.[38](#tca13229-bib-0038){ref-type="ref"} Systemic inflammation is the main contributor to malnutrition and cachexia in cancer patients.[39](#tca13229-bib-0039){ref-type="ref"}, [40](#tca13229-bib-0040){ref-type="ref"}, [41](#tca13229-bib-0041){ref-type="ref"} Furthermore, there is a close relationship between systemic inflammation and tumor progression and metastasis.[42](#tca13229-bib-0042){ref-type="ref"}, [43](#tca13229-bib-0043){ref-type="ref"}, [44](#tca13229-bib-0044){ref-type="ref"} In SCLC, many studies have reported the association of inflammatory markers with the prognoses of patients.[10](#tca13229-bib-0010){ref-type="ref"}, [45](#tca13229-bib-0045){ref-type="ref"}, [46](#tca13229-bib-0046){ref-type="ref"}, [47](#tca13229-bib-0047){ref-type="ref"}, [48](#tca13229-bib-0048){ref-type="ref"}, [49](#tca13229-bib-0049){ref-type="ref"} Because the GNRI reflects both systemic inflammation and cachexia, which result in adverse clinical outcomes, the GNRI may be a prognostic factor in SCLC patients.

We identified nutritional markers that were prognostic in ED‐SCLC. The GNRI was closely and positively correlated with the PNI and BMI. In addition to the GNRI, a low PNI was also associated with worse OS in a univariate analysis, but not associated with PFS. In a multivariate analysis, the PNI was not an independent prognostic factor for OS after adjusting for the GNRI. BMI did not show any prognostic value for PFS or OS. Several studies have compared the clinical impacts of nutritional markers, including the GNRI, in various malignancies. Patients with a low GNRI had 3.4 times more postoperative respiratory complications than those with a high GNRI after esophagectomy for esophageal cancer, whereas there was no difference between the low and high PNI groups.[50](#tca13229-bib-0050){ref-type="ref"} Another study of esophageal cancer patients who underwent curative esophagectomy reported that the GNRI and PNI had similar prognostic values.[20](#tca13229-bib-0020){ref-type="ref"} In nonmetastatic renal cell carcinoma, the low GNRI group had 3.2 times longer cancer‐specific survival compared with the high GNRI group, but BMI did not have any prognostic value.[51](#tca13229-bib-0051){ref-type="ref"} A study of surgically‐treated elderly patients with non‐SCLC reported that the GNRI was the only independent prognostic factor for OS when compared with the PNI, BMI, and controlling nutritional status.[52](#tca13229-bib-0052){ref-type="ref"} Because of a scarcity of data and discordant cutoff values of the markers, it was difficult to conclude which one was the most appropriate prognostic factor among the nutritional markers. However, when considering the results of present and previous studies, the GNRI may be as good as other nutritional markers as a prognostic indicator in SCLC.

Another purpose of this study was to determine whether the GNRI could identify patients having a favorable outcome from either the IP or EP regimens. In the EP arm, there was a significant difference in PFS among the GNRI groups, and this trend was clearer in OS (no risk vs. moderate/major risk group, 13.3 vs. 7.7 months). In contrast, no difference in PFS was observed regardless of the GNRI, and the discrimination of OS was also less clear in the IP arm. Given the higher response rate of the IP regimen, the IP regimen may be more effective than the EP regimen in patients with a low GNRI value who have a poor prognosis. However, this finding was obtained from a subgroup analysis, and there was no statistical difference in median OS between the IP and EP arms when the analysis was performed only in the moderate/major risk group (9.6 vs. 7.7 months; *P* = 0.174). In the original cohort, although the favorable OS of the IP arm was observed in males \<65 years of age and the ECOG PS 0--1 patient groups, the survival benefit was only 5--6 weeks in these populations.[29](#tca13229-bib-0029){ref-type="ref"} We suggest that the IP regimen does not clearly improve the prognoses of ED‐SCLC patients compared with the EP regimen, so additional studies are needed to identify patients who are likely to benefit from each regimen.

This study has some limitations. First, this was an unplanned subset analysis which was not powered to determine the prognostic role of the GNRI. In cancer patients, few studies have investigated the clinical impact of the GNRI using a prospective nonrandomized cohort.[21](#tca13229-bib-0021){ref-type="ref"}, [53](#tca13229-bib-0053){ref-type="ref"} To overcome the potential bias in an observational study, a randomized controlled trial comparing each GNRI risk group is needed. Second, nutritional and inflammatory assessments by other factors than the GNRI, PNI, and BMI were not performed due to limited information in this cohort. For example, mini‐nutritional assessment data, sarcopenia, GPS, and prognostic inflammatory and nutritional indices could not be assessed because of a lack of data regarding recent weight loss, muscle mass and quality, inflammatory cytokines, C‐reactive protein, and prealbumin.[7](#tca13229-bib-0007){ref-type="ref"}, [54](#tca13229-bib-0054){ref-type="ref"}, [55](#tca13229-bib-0055){ref-type="ref"}

In conclusion, this prospective study suggests that a low GNRI value was associated with poor prognoses for ED‐SCLC patients. The results support the importance of systemic inflammation and nutritional status in the clinical outcomes of SCLC patients. However, additional studies with comprehensive nutritional assessments are warranted to confirm our findings.
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